X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Multitude Therapeutics will provide proprietary T-Moiety linker technologies, co-developed with HySlink, to accelerate the discovery of preclinical ADC candidates (PCCs) and develop more novel bioconjugates for cancer treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Multitude Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 30, 2024
Details:
Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms to discover two undisclosed targets of preclinical investigational monoclonal antibodies for BioNTech to develop next-generation therapeutic product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Agreement January 11, 2024
Details:
Under the agreement, Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms and develop it into a first-in-class ADC based on its NMTi payload platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Myricx Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 21, 2023
Details:
Under the agreement, WuXi will provide comprehensive CMC development and current cGMP manufacturing services for IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, to treat Immune-Mediated Inflammatory Diseases.
Lead Product(s): TNAX101A
Therapeutic Area: Immunology Product Name: IMB1001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: IMIDomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2023
Details:
Under the agreement, PharmaEssentia will obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate.
Lead Product(s): Myeloid Immune Checkpoint Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: PharmaEssentia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 03, 2023
Details:
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody for the treatment of COVID-19.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: InflaRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 16, 2023
Details:
Under the terms of the expanded collaboration, WuXi XDC will provide IND-enabling CMC development services for Cidara’s CD73 oncology DFC program. CD421 targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers.
Lead Product(s): CD421
Therapeutic Area: Oncology Product Name: CD421
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration February 01, 2023
Details:
WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics’ proprietary technology platforms.
Lead Product(s): T-cell Engaging Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,500.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement January 05, 2023
Details:
Toregem BioPharma will have access to WuXi Biologics’ integrated CMC services in cell line development, cell culture development, biologics GMP manufacturing and related services. WuXi Biologics will support Toregem BioPharma on the TRG035 project for its IND application.
Lead Product(s): TRG035
Therapeutic Area: Rare Diseases and Disorders Product Name: TRG035
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Toregem BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2022
Details:
Under this collaboration, WuXi ATU will supply the materials, equipment, funding, and training required to further develop and commercialise TESSA technology in Singapore. BTI will contribute research expertise, facilities and access to its network of partners to support WuXi.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: A*STAR's Bioprocessing Technology Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
